View More Recent Stories
-
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Kiora Pharmaceuticals (KPRX) Granted EU Orphan Medicinal Product Designation for KIO-301
-
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
-
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation
-
Kiora Pharmaceuticals (KPRX) Appoints Lisa Walters-Hoffert to its Board
-
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
-
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
